Table of Contents Author Guidelines Submit a Manuscript
Journal of Cancer Epidemiology
Volume 2012 (2012), Article ID 291704, 13 pages
http://dx.doi.org/10.1155/2012/291704
Research Article

Comorbidities and Concomitant Medication Use in Men with Prostate Cancer or High Levels of PSA Compared to Matched Controls: A GPRD Analysis

1Quantitative Sciences Division, Worldwide Epidemiology, Research and Development, GlaxoSmithKline, Collegeville, PA 19426, USA
2Quantitative Sciences Division, Worldwide Epidemiology, Research and Development, GlaxoSmithKline, Research Triangle Park, NC 27709, USA
3WREN Group, EPIPharmaCo Ltd., Buxton, UK

Received 4 November 2011; Revised 2 February 2012; Accepted 2 February 2012

Academic Editor: Emanuela Taioli

Copyright © 2012 Haojie Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Ferlay, C. Y. Shin, F. Bray, D. Forman, C. Mathers, and D. M. Parkin, “GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10,” International Agency for Research on Cancer, Lyon, France, 2010, http://globocan.iarc.fr.
  2. Cancer Research UK, 2011, http://info.cancerresearchuk.org/cancerstats/types/prostate/?script=true.
  3. J. W. W. Coebergh, M. L. G. Janssen-Heijnen, P. N. Post, and P. P. A. Razenberg, “Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of The Netherlands in 1993–1996,” Journal of Clinical Epidemiology, vol. 52, no. 12, pp. 1131–1136, 1999. View at Publisher · View at Google Scholar · View at Scopus
  4. P. L. Marr, E. P. Elkin, S. A. Arredondo, J. M. Broering, J. DuChane, and P. R. Carroll, “Comorbidity and primary treatment for localized prostate cancer: data from CaPSURE,” Journal of Urology, vol. 175, no. 4, pp. 1326–1331, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. M. V. Meng, E. P. Elkin, S. R. Harlan, S. S. Mehta, D. P. Lubeck, and P. R. Carroll, “Predictors of treatment after initial surveillance in men with prostate cancer: results from capsure,” Journal of Urology, vol. 170, no. 6 I, pp. 2279–2283, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. L. V. Van De Poll-Franse, S. Houterman, M. L. G. Janssen-Heijnen, M. W. Dercksen, J. W. W. Coebergh, and H. R. Haak, “Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis,” International Journal of Cancer, vol. 120, no. 9, pp. 1986–1992, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. H. I. Hall, W. A. Satariano, T. Thompson, K. E. Ragland, S. K. Van Den Eeden, and S. Selvin, “Initial treatment for prostate carcinoma in relation to comorbidity and symptoms,” Cancer, vol. 95, no. 11, pp. 2308–2315, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Houterman, M. L. G. Janssen-Heijnen, A. J. M. Hendrikx, H. A. Van Den Berg, and J. W. W. Coebergh, “Impact of comorbidity on treatment and prognosis of prostate cancer patients: a population-based study,” Critical Reviews in Oncology/Hematology, vol. 58, no. 1, pp. 60–67, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. L. C. Harlan, A. Potosky, F. D. Gilliland et al., “Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study,” Journal of the National Cancer Institute, vol. 93, no. 24, pp. 1864–1871, 2001. View at Google Scholar · View at Scopus
  10. C. B. Begg, E. R. Riedel, P. B. Bach et al., “Variations in morbidity after radical prostatectomy,” New England Journal of Medicine, vol. 346, no. 15, pp. 1138–1144, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Froehner, R. Koch, R. Litz, A. Heller, S. Oehlschlaeger, and M. P. Wirth, “Comparison of the American Society of Anesthesiologists Physical Status classification with the Charlson score as predictors of survival after radical prostatectomy,” Urology, vol. 62, no. 4, pp. 698–701, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. H. H. Chao, T. Mayer, J. Concato, M. G. Rose, E. Uchio, and W. K. Kelly, “Prostate cancer, comorbidity, and participation in randomized controlled trials of therapy,” Journal of Investigative Medicine, vol. 58, no. 3, pp. 566–568, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. I. M. Thompson, D. P. Ankerst, C. Chi et al., “Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/mL or lower,” Journal of the American Medical Association, vol. 294, no. 1, pp. 66–70, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. National Health Service UK, 2011, http://www.cancerscreening.nhs.uk/prostate/index.html.
  15. World Health Organization, “International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10),” 2010, http://apps.who.int/classifications/icd10/browse/2010/en.
  16. A. Agresti, Categorical Data Analysis, Wiley, Hoboken, NJ, USA, 2nd edition, 2002.
  17. World Health Organization, “International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10),” 2000, http://www.websters-online-dictionary.org/definitions/ICD-10?cx=partner-pub-0939450753529744%3Av0qd01-tdlq&cof=FORID%3A9&ie=UTF-8&q=ICD-10&sa=Search#906.
  18. C. D. Berg, G. L. Andriole, E. D. Crawford et al., “Mortality results from a randomized prostate-cancer screening trial,” New England Journal of Medicine, vol. 360, no. 13, pp. 1310–1319, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. F. H. Schröder, M. J. Roobol, G. L. Andriole, and N. Fleshner, “Defining increased future risk for prostate cancer: evidence from a population based screening cohort,” Journal of Urology, vol. 181, no. 1, pp. 69–74, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Hugosson, S. Carlsson, G. Aus et al., “Mortality results from the Göteborg randomised population-based prostate-cancer screening trial,” The Lancet Oncology, vol. 11, no. 8, pp. 725–732, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. H. P. Burden, C. R. Davis, S. Tate, R. Persad, C. H. Holmes, and K. Whittington, “The trends in prostate specific antigen usage amongst United Kingdom urologists—a questionnaire based study,” BMC Urology, vol. 8, no. 1, article 17, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Brett, E. Watson, P. Hewitson et al., “PSA testing for prostate cancer: an online survey of the views and reported practice of General Practitioners in the UK,” BMC Family Practice, vol. 6, article 24, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. F. Mols, I. J. Korfage, A. J. J. M. Vingerhoets et al., “Bowel, urinary, and sexual problems among long-term prostate cancer survivors: a population-based study,” International Journal of Radiation Oncology Biology Physics, vol. 73, no. 1, pp. 30–38, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. E. Ream, A. Quennell, L. Fincham et al., “Supportive care needs of men living with prostate cancer in England: a survey,” British Journal of Cancer, vol. 98, no. 12, pp. 1903–1909, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. M. H. Blanker, F. P. M. J. Groeneveld, A. Prins, R. M. D. Bernsen, A. M. Bohnen, and J. L. H. R. Bosch, “Strong effects of definition and nonresponse bias on prevalence rates of clinical benign prostatic hyperplasia: the Krimpen study of male urogenital tract problems and general health status,” British Journal of Urology International, vol. 85, no. 6, pp. 665–671, 2000. View at Publisher · View at Google Scholar · View at Scopus
  26. R. M. Martin, L. Vatten, D. Gunnell, and P. Romundstad, “Blood pressure and risk of prostate cancer. Cohort Norway (CONOR),” Cancer Causes and Control, vol. 21, no. 3, pp. 463–472, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Altimari, A. D. Grigioni, E. Benedettini et al., “Diagnostic role of circulating free plasma DNA detection in patients with localized prostate cancer,” American Journal of Clinical Pathology, vol. 129, no. 5, pp. 756–762, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Pinkawa, K. Fischedick, B. Gagel et al., “Impact of age and comorbidities on health-related quality of life for patients with prostate cancer: evaluation before a curative treatment,” BMC Cancer, vol. 9, article 296, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Yancik, R. J. Havlik, M. N. Wesley et al., “Cancer and comorbidity in older patients: a descriptive profile,” Annals of Epidemiology, vol. 6, no. 5, pp. 399–412, 1996. View at Publisher · View at Google Scholar · View at Scopus
  30. F. H. Schröder, J. Hugosson, M. J. Roobol et al., “Screening and prostate-cancer mortality in a randomized european study,” New England Journal of Medicine, vol. 360, no. 13, pp. 1320–1328, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Jick, S. S. Jick, and L. E. Derby, “Validation of information recorded on general practitioner based computerised data resource in the United Kingdom,” British Medical Journal, vol. 302, no. 6779, pp. 766–768, 1991. View at Google Scholar · View at Scopus